NCT06507059View on ClinicalTrials.gov

Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals

PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 19, 2024

Primary Completion Date

July 1, 2025

Study Completion Date

December 31, 2026

Conditions
HIV-1-infectionNon-Adherence, Medication
Interventions
DRUG

cabotegravir/rilpivirine (600mg/ 900mg)

Immediate switch from oral antiretroviral to long-acting injectables

DRUG

Antiretroviral Combinations

Standard all-oral antiretroviral combinations

Trial Locations (4)

105

RECRUITING

Chang Gung Memorial Hospital, Taipei, Taipei

204

RECRUITING

Chang Gung Memorial Hospital, Keelung, Keelung

330

RECRUITING

Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan District

333

RECRUITING

Chang Gung Memorial Hospital, Linkou, Taoyuan District

All Listed Sponsors
collaborator

Taoyuan General Hospital

OTHER_GOV

lead

Chang Gung Memorial Hospital

OTHER